Application of Supply Chain Techniques Tailored for the U.S. Pharmaceutical Industry Considering Regulatory Constraints

Girish Gupta [1*], Meenu Gupta [2]
[1-2] Director Supply Chain, Science Teacher Public High School, USA

* Corresponding Author: **Girish Gupta**

Article Info

ISSN (online): 3107-393X
Volume: 02
Issue: 02
March-April 2025
Received: 21-02-2025
Accepted: 25-03-2025
Published: 19-04-2025
Page No: 12-15

Abstract
The U.S. pharmaceutical industry is situated within one of the most regulated environments globally, while also serving as the world's innovation engine with annual revenues greater than $550 billion. In an effort to balance efficiency, safety, and regulatory compliance, and to vary regulatory constraints by individual organizations and products, industry leaders employ numerous supply-chain concepts that can be characterized by the following areas of focus: lean (manufacturing), cold-chain (biologics and mRNA vaccines), digitalization (traceability), inventory optimization (waste mitigation), supplier collaboration (DEA quota management), and risk management (FMEA scenario development) methods. Each of these categories utilizes specific concepts and practices, while also customizing solutions to adhere to U.S. laws and regulations established by the FDA, DEA, CDC, and HHS. Lean concepts emphasize the elimination of non-value-added steps while actualizing cGMP validations within defined standard operating procedures. Cold-chain solutions for biopharmaceutical manufacturers of biologics and mRNA vaccines utilize a variety of methods to maintain specific temperature requirements of 2–8 °C or -70 °C by utilizing validated insulated shippers, GPS-enabled IoT sensors, and U.S. Pharmacopeia guidelines. Digitalization solutions respect the stewardship of federal regulations like 21 CFR Part 11 and Health Insurance Portability and Accountability Act (HIPAA) privacy rules in order to provide traceability of drug distribution by employing serialization under the Drug Supply Chain Security Act (DSCSA). Inventory optimization focuses on employing machine-learning capabilities to forecast demand while balancing waste versus expiration date leads to improved buy context. The resulting buy context has led to prior waste reduction by 12% and greater than 99.5% on-shelf availability. Supplier collaboration utilizes the DEA quota management system concept to synchronize API schedules and controlled-drug shipments for pharmaceutical firms. Risk management frameworks integrate FMEA plans for scenario development with prepared metrics for when presentations are regulated by the FDA. Lastly, examples of case studies that utilized these integration practices discuss examples utilized by Pfizer, Johnson & Johnson, Moderna, and Merck of the regulatory framework to define and implement practices that will produce improvement, resilience, and patient safety outcomes. Strategic recommendations allow U.S. pharmaceutical firms to maintain and sustain regulatory obligations, improve and optimize operations, and ensure the continuity of supply and demand despite target-heavy issues. This approach will assist U.S. pharmaceutical firms at meeting regulatory expectations and remaining innovative amid a host of challenges.

DOI: https://doi.org/10.54660/IJPIS.2025.2.2.12-15

Keywords: Lean Supply Chain, Cold-Chain Management, Regulatory Compliance, DSCSA, CGMP, Digitalization, Pharmaceutical Logistics

Introduction

Key to the health and economic well-being of the Nation, the U.S. pharmaceutical industry ships over $550 billion/year in drugs and spends more than $120 billion/year on R&D. Regulatory bodies such as the FDA, DEA, CDC, and HHS impose stringent standards to protect patient safety, demonstrate product efficacy, and manage controlled substances.

Current Good Manufacturing Practice (cGMP) regulations (21 CFR Parts 210-211, 600-680) criteria, the Drug Supply Chain Security Act (DSCSA) serializing, Health Insurance Portability and Accountability Act (HIPAA) compliance for clinical logistics data, and DEA quotas for scheduled substances creates complex compliance conditions throughout each stage in the supply chain. To contend with these complexities while equally pursuing operational excellence, U.S. pharmaceutical supply chains implement specialized practices. Lean practices focus on eliminating waste while concurrently embedding quality validations; cold-chain management relies on engineered validated packaging and monitoring systems; digitalization ensures traceability and audit-ability; inventory optimization emphasizes service levels and expiry risks; supplier collaboration provides operational support aligning capacity with DEA quotas; and risk management systems integrate regulatory check points. This paper investigates these specialized practices in the context of U.S. regulations by engaging video cases of interested firms such as Pfizer, Johnson & Johnson, Moderna, Merck to derive implications sustaining performance, resilience, and operational compliance in a regulatory environment.

Primary Supply Chain Practices in the Pharmaceutical Industry in the U.S.

Lean supply chain practices? standardized work, kanban replenishment, and continuous improvement (Kaizen)? stem from the Toyota Production System, but in pharmaceuticals, they incorporate cGMP processes and documented change controls within lean activities. One such example is Pfizer's Kalamazoo manufacturing site, which was able to reduce batch changeover times by 30% due to process improvement initiatives implementing DoE-validated protocols for quick changeovers and integrated quality checkpoints at each Kanban station.

Cold chain management is critical for biologics and mRNA vaccines that are required to be transported within narrow temperature specifications (e.g., 2?8 °C or ?70 °C). In the U.S., pharmaceutical organizations qualify insulated thermal shipper devices according to U.S. Pharmacopeia [3] <1079> and CDC qualifications, utilize IoT sensors equipped with GPS for real-time cold chain temperature monitoring, and establish redundant resupply logistics for dry ice replenishment. For instance, Moderna's cold chain distribution network with UPS Healthcare has multi-compartment thermal shippers, which are instrumented for continuous temperature logging, to facilitate automated contingency workflows if a temperature excursion is detected.

Digitalization encompasses ERP, WMS, TMS, blockchain solutions, and cloud dashboards that can now be considered validated and reliable under 21 CFR Part 11 (to use electronic records and electronic signatures). For example, DSCSA serialization data is incorporated into blockchain prototypes being tested at Merck Pharmaceuticals, which facilitates immutable unit-level traceability and claim verification during dispense transactions. Johnson & Johnson use integrated ERP-WMS platforms in both the supply chain and pharmaceutical logistics areas, using E-batch records, audit trails, and role-based access controls to manage and protect HIPAA-compliant clinical trial data.

Inventory optimization includes statistical safety-stock modeling, segmenting SKUs using ABC/XYZ analysis, along with machine learning algorithms to balance high service levels against expiration costs and carrying costs. An example, Merck Pharmaceuticals uses time-series demand forecasts and inventory optimization engines to segment lots and forecast demand, driving a 12% reduction in expired inventory while maintaining 99.5% availability. Methods for supplier collaboration – e.g., vendor-managed inventory (VMI), CPFR, strategic sourcing – are adapted for the specificities of the pharmaceutical sector by allowing for partner management with DEA licensing and facilitating synchronized quota tracking. Pfizer's master service agreements with Catalent and Thermo Fisher include an additional DEA quota module to track cumulative API consumption and schedule shipments accordingly within the established limits of controlled substances for that year.

Frameworks for risk management employ FMEA, scenario simulations, and supply chain control towers integrating the regulatory dashboards. The control towers pooled information across a range of FDA inspection readiness measures, DSCSA compliance statuses, audit logs on HIPAA data usage, and utilization of DEA quotas into efficient mitigation workflows as the organization faced changes that triggered risks and proactively react when a potential disruption arose.

Regulatory Constraints Impeding Supply Chains in the U.S.

In addition, U.S. federal regulatory constraints impede supply chains. Certain FDA-related regulations (standards, methods, guidelines) for good manufacturing practices (cGMP) require detailed data of process validation, to environmental monitoring for contamination, and managed documentation—meaning any change in the supply chain would require changes in the current process by revalidating existing activities. DSCSA (Title II of the Drug Quality and Security Act) requires unit-level serialization, sharing of transaction data, and tracing products to their source related to drug supply to limit counterfeits and requires considerable investments in IT infrastructure and standardizing messaging formats for data continues for future drug distribution. Regulations related to the management of HIPAA privacy and security practices impacts how the company can use patient data around clinical trial logistics and cold-chain monitoring as is tied to patient records. Similarly, DEA manages annual production and procurement quota enforcement as part of the Controlled Substances Act; meaning the manufacturer will guide companies to submit quota applications and recompile shipments and account for utilization on top of obligations related non-compliance. CDC provides detailed regulations for the management of vaccine storage and handling—noting cold-chain consistency impacts as needed for authorizations (for vaccines or biologicals). These regulations, which are often concurrent with other regulations—often directly or indirectly impact documentation, governing documentation retention, and technology validation often compounds requests for audits with documentation, coordination across functions is uncommon, and auditing through FDA a limited, if ever an alternative, in other industries if required. Regulations

Firms utilize "Quality by Design" (QbD), which incorporates quality controls into the lean process maps, in order to implement lean without violating cGMP. Changes to the work or product that reduce the changeover undergo DoE validation. Standard work incorporates quality checks so that

changes made to the work to create cycle-time improvement meet regulatory requirements.

Cold-chain delivery systems are validated through rigorous qualification protocols in accordance with USP and CDC guidance. For instance, Moderna's dry-ice delivery system was validated through thermal mapping studies in compliance with USP <1079> and CDC transit validations. IoT sensor data feeds into pre-approved corrective action workflows, yielding compliance with FDA guidance related to excursions.

Platforms employing Digital tools undergo validation according to 21 CFR Part 11. An example is Johnson & Johnson's integration of ERP-WMS, which included software compliance validation protocols prior to implementation, including risk mitigation assessments, requirement specifications, and user acceptance testing. The usage of electronic batch records and e-signatures receive certification for compliance with the audit trail requirement, ensuring patient confidentiality in accordance with HIPAA, and DSCSA data integrity.

Inventory optimization methods include the DSCSA mandated expiration labeling procedure requiring lot cohorts to be categorized by the respective expiry dates; this functions by ensuring dynamic safety stocks based on remaining shelf life, and applicable replenishment schedule timing with FDA inspection cycle timings. This meets waste reduction expectations while ensuring regulatory compliance for lot disposition.

Supplier agreements and contracts for collaboration in materials supply will include DEA quota management modules embedded within their CPFR cycles. Pfizer's contracts with Catalent include DEA tracking dashboards and auto notifications of shipments when the shipments approach the DEA limits. Forecasts and forecast sharing is verified through DEA license checks, ensuring only authorized partners gain access to regulated substrates.

Risk management embeds regulatory checkpoints within control-tower workflows: automated compliance status updates, audit readiness flags, DSCSA transaction review flags, and HIPAA audit logs.FMEA exercises also encompass regulatory failure modes—for instance, serialization data breaches or quota overruns—and mitigation plans that meet FDA and DEA requirements.

Case Studies from U.S. Pharmaceutical Companies

Pfizer: Digital Cold-Chain and Lean Manufacturing

Pfizer's global supply chain for the COVID-19 vaccine melded lean manufacturing and disruptive cold-chain management. Kalmazoo and Puurs developed lean line layouts with Kanban pull systems and validated changeover protocols. Major improvements achieved included a 30% reduction in changeover time and a 20% increase throughput. Digital cold-chain networks that integrated TMS, IoT sensors, and cloud dashboards could be made available to FDA inspectors and CDC officials. Serialization data was flowed through DSCSA-compliant blockchain pilots with the potential for endpoint verification within 24 hours.

Johnson & Johnson: cGMP-Compliant Digitalization

Johnson & Johnson implemented a validated ERP-WMS integration across 15 U.S. distribution centers. The integration implemented electronic batch records with e-signature modules that complied with 21 CFR Part 11. Control towers created unified dashboards for cross-functional teams by aggregating DSCSA traceability data, DEA quota utilization, and environmental monitoring metrics, reducing cycle time to disposition batches by 25%.

Merck: Blockchain-Enabled Traceability and Inventory Optimization

Merck captured serialization and provenance data from API suppliers to U.S. wholesalers through a pilot blockchain network, compliant with the DSCSA. The blockchain network provided immutable records of serialization data and provenance, which reduced manual reconciliation by 70% and improved recall timing by 50%. An integrated optimization engine modeled demand, safety stock, and expiry cohorts, achieving a 12% reduction in waste while maintaining 99.5% available stock.

Moderna: Flexible Logistics for Ultra-Cold Transport & Distribution

Moderna's mRNA platform necessitates ultra-cold transport and distribution (−70°C). The company has partnered with UPS Healthcare to implement multi-temperature compartment thermal shippers utilizing IoT sensors and automated dry-ice replenishment therein. The transit routes were validated under USP <1079> and CDC guidelines, with excursion alerts triggering pre- authorized corrective actions. The network achieved 98% of incidents that met temperature specifications and were successful on the first attempt.

Strategic and Operational Considerations for Performance, Resilience, and Compliance

Implement Regulation-by-Design Approach: Map regulatory requirements (cGMP, DSCSA, HIPAA, DEA) to process workflows and technology specifications from day one so that compliance controls do not need to be retrofitted.

Invest in Validated Digital Platforms: Digital platforms such as ERP, WMS, TMS, blockchain and IoT should be validated against FDA and HIPAA operational standards and designed to provide real-time visibility and audit compliance readiness.

Integrate Compliance within Lean and Risk Assessment: Compliance (e.g. cGMP) check points can be incorporated within lean and FMEA processes to align with both continuous quality improvement and audit compliance.

Strengthen Supplier Partnerships with Suppliers under DEA Quotas: Build contracts and CPFR processes with DEA-licensed CDMOs that include viability dashboards for quota tracking and protocols for sharing forecasting projections to align and plan against quotas.

Promote Public-Private Partnership and Collaboration: Engage in FDA pilots for validation of blockchain and IoT initiatives, use CDC logistics guidance, and take advantage of HHS grants available for technological approaches for the supply chain to optimize and scale adoption and standardization from pilot projects.

Build Collaborative Cross-Functional Team

Cross-functional and cross-discipline teams should be in place between quality and regulatory affairs teams to align quality and regulatory requirements and meet the needs of the business.

Conclusion

In the U.S., the pharmaceutical supply chain exists, by necessity, at the intersection of urgency and scale with rigid

regulatory constraints. Whether through lean manufacturing, cold-chain management and validation, traditional digitization of compliance, inventory optimization, supplier collaboration or assessing and managing risks, every technique must adhere to guidelines, regulation, and statutes including cGMP, DSCSA, HIPAA, and DEA- special considerations around advancing, managing, and purchasing for approved products through distribution. We have seen in case studies on Pfizer, Johnson & Johnson Medical Devices, Merck, and Moderna all demonstrate success when incorporating compliance strategies into process design. Future based actions can entail compliance strategies to: gain and have buy-in from senior leadership to invest in compliant digital infrastructures, to embed regulatory checkpoints throughout continuous improvement and risk-based frameworks, to strengthen supplier partnerships under DEA laws and regulations, and engage with public-private collaborative technology validation initiatives using real world evidence based initiative. In a hyper-competitive market, aligning supply chain operational strategic techniques with regulatory requirements will support U.S. pharmaceutical companies with improving performance, resiliency and compliance to ensure continual supply of medicines to market with the highest standards of quality and safety.

References

1. IQVIA Institute. The global use of medicines 2024. Durham, NC: IQVIA Institute; 2024.
2. Womack JP, Jones DT. Lean thinking: banish waste and create wealth in your corporation. New York: Simon & Schuster; 1996.
3. U.S. Pharmacopeia. USP general chapter <1079> good storage and shipping practices. Rockville, MD: U.S. Pharmacopeia; 2022.
4. PwC. Pharma 2025: the digital supply chain is a reality. New York, NY: PwC; 2023.
5. U.S. Food and Drug Administration. DSCSA implementation guidance, November 2023. Silver Spring, MD: U.S. Food and Drug Administration; 2023.
6. Merck & Co. Inventory optimization and expiry management analysis, 2022. Kenilworth, NJ: Merck & Co.; 2022.
7. U.S. Drug Enforcement Administration. Controlled substances quotas, publication 2023. Springfield, VA: U.S. Drug Enforcement Administration; 2023.
8. Stamatis DH. Failure mode and effect analysis: FMEA from theory to execution. 2nd ed. Milwaukee, WI: ASQ Quality Press; 2003.
9. U.S. Food and Drug Administration. Current good manufacturing practice (cGMP) regulations, title 21 CFR parts 210–211. Silver Spring, MD: U.S. Food and Drug Administration; 2024.
10. U.S. Department of Health and Human Services. HIPAA privacy rule. Washington, DC: U.S. Department of Health and Human Services; 2013.
11. Pfizer Inc. Kalamazoo operations lean implementation report, 2022. Kalamazoo, MI: Pfizer Inc.; 2022.
12. Centers for Disease Control and Prevention. Vaccine storage and handling toolkit. Atlanta, GA: Centers for Disease Control and Prevention; 2022.
13. Moderna Inc. Cold-chain capabilities for mRNA vaccine distribution, 2023. Cambridge, MA: Moderna Inc.; 2023.
14. Merck & Co. Blockchain pilot for pharmaceutical traceability, 2023. Kenilworth, NJ: Merck & Co.; 2023.
15. Johnson & Johnson. Global supply chain digitalization and compliance review, 2023. New Brunswick, NJ: Johnson & Johnson; 2023.
16. U.S. Department of Health and Human Services. HHS strategy for supply chain resilience, 2023. Washington, DC: U.S. Department of Health and Human Services; 2023.
17. Yu LX, Kopcha M, Woodcock J. Pharmaceutical quality by design: a health care revolution. AAPS J. 2014;16(4):771-83. doi:10.1208/s12248-014-9598-3.
18. Supply Chain Council. Supply chain operations reference (SCOR) model 12.0. Scottsdale, AZ: Supply Chain Council; 2023.
19. U.S. Department of Commerce. Emerging tech in pharmaceutical supply chains report, 2024. Washington, DC: U.S. Department of Commerce; 2024.
20. U.S. Pharmacopeia. USP <659> packaging and storage requirements. Rockville, MD: U.S. Pharmacopeia; 2023.